This website is intended for healthcare professionals only.
TAKING AIM AT IDH1 MUTATIONS TO IMPROVE OUTCOMES IN AML
Taking aim at IDH1 mutations to improve outcomes in AML
Dr. Andre Schuh, University Health Network/
Princess Margaret Cancer Centre Toronto, Ontario, Canada
This webinar focuses on the latest data for actionable mutation – mIDH1 – in AML. Data will be presented from the AGILE trial of ivosidenib + azacitidine for adult patients with mIDH intensive chemotherapy ineligible AML.
Key points covered
Taking aim at IDH1 mutations to improve outcomes in AML
What is IDH enzyme?
What is IDH mutation, and what is its role in leukemogenesis?
Data from the AGILE trial: efficacy and toxicity profile of ivosidenib + azacitidine vs placebo + azacitidine in first-line intensive chemotherapy ineligible mIDH1 AML
Webinar Replay
Featured Speakers
Dr. Andre Schuh
University Health Network/ Princess Margaret Cancer Centre Toronto, Ontario, Canada
Dr. Andre Schuh is a staff physician at the University Health Network/Princess Margaret Cancer Centre, Toronto, ON. He served as head of the leukemia program at Princess Margaret from 2010–2014, and as medical director, malignant hematology from 2012–2018. He obtained his medical degree at the University of Toronto, and thereafter received subspecialty certification in internal medicine and in hematology, followed by a 4-year molecular biology fellowship. Dr Schuh’s current interests include acute leukemia management and clinical trials (especially in the older patient), myelodysplastic syndromes, and the development of province- and country-wide leukemia management strategies.
